Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E104.70 EPS (ttm)1.11 Insider Own0.10% Shs Outstand229.86M Perf Week-8.70%
Market Cap26.69B Forward P/E13.35 EPS next Y8.70 Insider Trans-5.09% Shs Float222.05M Perf Month-9.08%
Income251.80M PEG5.65 EPS next Q1.83 Inst Own98.00% Short Float1.94% Perf Quarter-1.00%
Sales3.91B P/S6.82 EPS this Y23.50% Inst Trans1.65% Short Ratio2.80 Perf Half Y-4.16%
Book/sh41.14 P/B2.82 EPS next Y14.13% ROA1.10% Target Price163.29 Perf Year5.57%
Cash/sh6.68 P/C17.39 EPS next 5Y18.52% ROE1.70% 52W Range102.10 - 140.77 Perf YTD-2.91%
Dividend- P/FCF78.20 EPS past 5Y11.10% ROI4.70% 52W High-17.52% Beta1.07
Dividend %- Quick Ratio2.70 Sales past 5Y25.60% Gross Margin89.20% 52W Low13.72% ATR5.08
Employees2525 Current Ratio3.20 Sales Q/Q19.50% Oper. Margin8.60% RSI (14)43.46 Volatility3.72% 4.51%
OptionableYes Debt/Eq0.35 EPS Q/Q343.90% Profit Margin3.90% Rel Volume0.71 Prev Close118.52
ShortableYes LT Debt/Eq0.32 EarningsOct 24 BMO Payout0.00% Avg Volume1.54M Price116.11
Recom1.80 SMA20-3.85% SMA50-6.17% SMA200-3.92% Volume1,093,600 Change-2.03%
Aug-07-18Downgrade Stifel Buy → Hold $154 → $130
Feb-05-18Upgrade Evercore ISI In-line → Outperform
Jan-18-18Resumed Credit Suisse Outperform $147
Jan-04-18Downgrade Raymond James Strong Buy → Outperform
Dec-18-17Upgrade Robert W. Baird Neutral → Outperform $150
Oct-23-17Resumed Piper Jaffray Overweight $170
Sep-15-17Initiated RBC Capital Mkts Outperform $161
Sep-13-17Reiterated Leerink Partners Outperform $170 → $182
Sep-13-17Reiterated Deutsche Bank Buy $153 → $158
Sep-05-17Upgrade JP Morgan Neutral → Overweight
Aug-17-17Initiated Evercore ISI In-line $137
Jul-28-17Upgrade Oppenheimer Perform → Outperform
May-25-17Upgrade Morgan Stanley Equal-Weight → Overweight
May-23-17Downgrade JP Morgan Overweight → Neutral
Mar-30-17Initiated UBS Buy $138
Mar-02-17Initiated Instinet Buy $148
Feb-17-17Reiterated RBC Capital Mkts Outperform $187 → $177
Dec-22-16Reiterated RBC Capital Mkts Outperform $188 → $187
Dec-15-16Initiated Oppenheimer Perform
Dec-13-16Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-12-18 10:50AM  AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark Zacks
Nov-08-18 11:11AM  Alexion Pharmaceuticals Dropped 19.4% in October, but the Business Remains Strong Motley Fool
Nov-07-18 04:30PM  Alexion to Present at Credit Suisses 27th Annual Healthcare Conference Business Wire
Nov-06-18 09:30AM  Is Alexion Pharmaceuticals (ALXN) Stock Outpacing Its Medical Peers This Year? Zacks
Nov-02-18 11:05AM  Alexion Completes Acquisition of Syntimmune Business Wire
08:15AM  Report: Developing Opportunities within General Electric, Arch Capital Group, China Petroleum & Chemical, Alexion Pharmaceuticals, GAIN Capital, and Sony Future Expectations, Projections Moving into 2018 GlobeNewswire
08:00AM  Today's Research Reports on Trending Tickers: Alexion Pharmaceuticals and OncoSec Medical ACCESSWIRE
Nov-01-18 08:10PM  Edited Transcript of ALXN earnings conference call or presentation 24-Oct-18 12:00pm GMT Thomson Reuters StreetEvents +6.81%
03:34PM  Biotech ETFs in Focus on String of Q3 Earnings Beat Zacks
10:23AM  Alexion Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting Business Wire
Oct-31-18 02:08PM  Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal Zacks
05:19AM  Alexion Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-24-18 11:28PM  Alexion Pharmaceuticals Inc (ALXN) Q3 2018 Earnings Conference Call Transcript Motley Fool -9.76%
04:41PM  Big Cap 20 Biotech Stock Dives On Mixed Third-Quarter Revenue Investor's Business Daily
10:46AM  Alexion enters RNA gene-silencing field with $637M Dicerna deal American City Business Journals
08:40AM  [$$] Alexion 3Q Profit Up, Boosts Revenue Guidance The Wall Street Journal
08:00AM  Alexion Pharmaceuticals (ALXN) Tops Q3 Earnings Estimates Zacks
07:49AM  Alexion stock rises 3% on Q3 beats, upbeat 2018 guidance MarketWatch
06:55AM  Alexion: 3Q Earnings Snapshot Associated Press
06:35AM  Alexion Reports Third Quarter 2018 Results Business Wire
06:30AM  Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases Business Wire
Oct-23-18 09:31AM  Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT Zacks
Oct-22-18 04:40PM  Alexion (ALXN) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-19-18 09:04PM  Berkshire Hathaway Stock Looks Cheap by Warren Buffetts Measure Barrons.com
Oct-17-18 10:32AM  Alexion Pharmaceuticals (ALXN) Q3 Earnings Preview: What to Know Ahead of the Release Zacks
Oct-11-18 09:00AM  Investor Expectations to Drive Momentum within Materion, Iridium Communications, Natural Health Trends, Revance Therapeutics, Baxter International, and Alexion Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Oct-10-18 10:10AM  Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again Zacks -5.05%
Oct-04-18 04:30PM  Alexion to Report Third Quarter 2018 Results on Wednesday, October 24, 2018 Business Wire
Oct-03-18 10:54AM  Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs Zacks
Oct-01-18 10:28AM  5 Best Biotech Stocks to Buy In October Zacks
Sep-27-18 10:38AM  Alexion (ALXN) to Acquire Biotech Syntimmune for $1.2 Billion Zacks
10:19AM  Company News For Sep 27, 2018 Zacks
08:00AM  Todays Research Reports on Stocks to Watch: Aldeyra Therapeutics and Alexion Pharmaceuticals ACCESSWIRE
Sep-26-18 05:39PM  The Dow Cant Handle the Feds Truth Barrons.com +5.13%
04:19PM  Here's Why The Stock Market Sold Off After The Fed Meeting Investor's Business Daily
03:59PM  Stock News Today: Biotechs Help Nasdaq 100 To Day Of Outperformance Investor's Business Daily
03:56PM  Deals of the day-Mergers and acquisitions Reuters
12:32PM  Alexion to acquire Boston startup Syntimmune for up to $1.2B American City Business Journals
08:26AM  Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars Zacks
07:09AM  Alexion to buy biotech firm Syntimmune for up to $1.2 bln Reuters
07:02AM  [$$] Alexion Pharmaceuticals to Buy Syntimmune for Up to $1.2 Billion The Wall Street Journal
06:51AM  Alexion Pharmaceuticals to buy Syntimmune for up to $1.2 billion, including potential milestone payments MarketWatch
06:42AM  Alexion to buy biotech firm Syntimmune for up to $1.2 bln Reuters
06:30AM  Alexion to Acquire Syntimmune Business Wire
Sep-25-18 06:05PM  Alexion's Soliris Successful in Phase III Study for NMOSD Zacks
04:30PM  Alexion to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology Business Wire
08:50AM  Alexion Pharmaceuticals (ALXN) Surges: Stock Moves 5.3% Higher Zacks
08:00AM  Today's Research Reports on Trending Tickers: Akcea Therapeutics and Alexion Pharmaceuticals ACCESSWIRE
Sep-24-18 11:30AM  Stocks - Pandora Gains in Pre-market; Tesla, Comcast Tumble Investing.com +5.34%
09:38AM  Stocks Slump As Trade War Intensifies; 3 Med Stocks Rally, Tilray Tumbles Investor's Business Daily
07:45AM  Stocks making the biggest move premarket: CMCSA, FOXA, P, SIRI, ALXN & more CNBC
06:30AM  Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire
Sep-07-18 04:30PM  Alexion to Present at Morgan Stanleys 16th Annual Global Healthcare Conference Business Wire
Sep-05-18 07:40AM  Nielsen names David Anderson CFO, effective Sept. 10 MarketWatch
Aug-29-18 04:30PM  Alexion to Present at Citis 13th Annual Biotech Conference Business Wire
Aug-22-18 11:43AM  Biotech Stock Roundup: Label Expansion of Regeneron's Eylea, Vertex's Kalydeco Zacks
Aug-21-18 11:15AM  Alexion's BLA for ALXN1210 Gets Priority Review From FDA Zacks
Aug-20-18 09:37AM  Stocks Jump At Starting Bell As This Dow Stock Retakes Buy Point Investor's Business Daily
06:30AM  FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the US Business Wire
Aug-10-18 01:56PM  Biotech ETFs in Focus on String of Q2 Earnings Beat Zacks
Aug-08-18 08:15AM  Recent Analysis Shows Washington Real Estate Investment Trust, FirstEnergy, Alexion Pharmaceuticals, Alaska Air Group, Fortune Brands Home & Security, and Baxter International Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-06-18 09:30AM  ALXN vs. RGNX: Which Stock Is the Better Value Option? Zacks
Aug-02-18 01:19AM  Edited Transcript of ALXN earnings conference call or presentation 26-Jul-18 12:00pm GMT Thomson Reuters StreetEvents -5.25%
Aug-01-18 12:14PM  5 Stocks Trading Near 52-Week High With More Upside in Store InvestorPlace
09:39AM  5 Stocks Trading Near 52-Week High With More Upside in Store Zacks
Jul-26-18 02:42PM  Vertex and Alexion Are Schooling Big Biotech Bloomberg
10:26AM  Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up Zacks
09:23AM  Alexion (ALXN) Tops Q2 Earnings and Revenues Beat Estimates Zacks
07:44AM  Alexion Pharmaceuticals (ALXN) Beats Q2 Earnings and Revenue Estimates Zacks
06:59AM  Alexion: 2Q Earnings Snapshot Associated Press
06:30AM  Alexion Reports Second Quarter 2018 Results Business Wire
Jul-25-18 03:45PM  6 Stocks to Buy for Trade War Protection Kiplinger
10:27AM  Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More Zacks
Jul-23-18 11:29AM  Is a Beat in Store for Alexion (ALXN) This Earnings Season? Zacks
Jul-19-18 09:50AM  ALXN or RGNX: Which Is the Better Value Stock Right Now? Zacks
09:45AM  ALXN vs. RGNX: Which Stock Is the Better Value Option? Zacks
09:21AM  Karyopharm Initiates NDA Submission Process for Selinexor Zacks
Jul-18-18 03:39AM  J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised) Zacks
Jul-17-18 04:04PM  J&J's (JNJ) Phase III Study for Invokana Halted Earlier Zacks
09:40AM  J&J (JNJ) Ordered to Pay $4.69 Billion in Talc Lawsuit (Revised) Zacks
08:33AM  Roche's Flu Drug Meets Primary Endpoint in Phase III Study Zacks
08:03AM  Alexion Pharmaceuticals (ALXN): Moving Average Crossover Alert Zacks
Jul-16-18 08:31AM  Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population Zacks
Jul-09-18 06:00AM  4 Biotechs on Verge of Big Breakouts Investopedia
Jul-05-18 08:37AM  3 Big Stock Charts for Thursday: Express Scripts Holding Co, Alexion Pharmaceuticals and Ventas InvestorPlace
Jun-28-18 04:30PM  Alexion to Report Second Quarter 2018 Results on Thursday, July 26, 2018 Business Wire
06:30AM  Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the European Union (EU) Business Wire
Jun-26-18 02:00PM  Is Alexion Pharmaceuticals Inc (NASDAQ:ALXN) A Financially Sound Company? Simply Wall St.
09:30AM  ALXN vs. RGNX: Which Stock Should Value Investors Buy Now? Zacks
Jun-21-18 11:49AM  3 Big Biotechs That Can Beat the Market Investopedia
Jun-20-18 05:03PM  Alexion (ALXN) Submits Application for ALXN1210 with FDA Zacks
08:32AM  Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash Zacks
07:52AM  5 Stocks That Are Screaming Buys Right Now TheStreet.com
05:56AM  Future home of PTC, Alexion could sell for $450M American City Business Journals
Jun-19-18 04:21PM  Why This Biotech Company Could Shock 2019 Sales Expectations Investor's Business Daily
06:30AM  Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S. Business Wire
Jun-15-18 10:37AM  Big Biotech Set for Earnings Blowout? Barrons.com
Jun-14-18 07:30AM  Alexion Announces Selection of Positive Phase 3 Clinical Data for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) for Late-Breaking Oral Presentation at Annual Conference of the European Hematology Association (EHA) Business Wire
Jun-13-18 10:34AM  Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod Zacks
07:20AM  Wired News Alexion Pharma and Complement Pharma Inked Deal to Co-develop Preclinical C6 Complement Inhibitor CP010 ACCESSWIRE
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops cPMP (cyclic Pyranopterin Monophosphate) (ALXN 1101) for molybdenum cofactor deficiency disease type A; and Samalizumab (ALXN6000), an immunomodulatory humanized monoclonal antibody. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Clancy Paul JEVP, Chief Financial OfficerJul 10Sale131.115,241687,14893,309Jul 12 05:23 PM
Franchini Indrani LallEVP, Chief Compliance OfficerJun 08Sale118.531,466173,76531,909Jun 12 04:52 PM
Goff BrianEVP & Chief Commercial OfficerJun 08Sale118.531,645194,98236,257Jun 12 04:51 PM
LAW ANNE-MARIEEVP and CHROJun 08Sale118.531,862220,70329,450Jun 12 04:51 PM
ORLOFF JOHN JEVP, Research & DevelopmentJun 08Sale118.532,115250,69131,790Jun 12 04:51 PM
COUGHLIN CHRISTOPHER JDirectorApr 30Buy120.7910,0001,207,90026,333May 02 05:42 PM
Wagner Heidi LSVP, Global Government AffairsFeb 28Sale118.6145453,84949,140Mar 01 05:25 PM
O'Neill JulieEVP. Global OperationsFeb 28Sale118.6168681,36642,787Mar 01 05:25 PM
Wagner Heidi LSVP, Global Government AffairsFeb 27Sale120.7224429,45649,594Mar 01 05:25 PM
O'Neill JulieEVP. Global OperationsFeb 27Sale120.72939113,35643,473Mar 01 05:25 PM
Goff BrianEVP & Chief Commercial OfficerFeb 08Sale116.311,651192,02828,962Feb 08 07:17 PM
Moriarty John BEVP & General CounselFeb 08Sale115.703,363389,09974,537Feb 08 07:16 PM
O'Neill JulieEVP. Global OperationsFeb 08Sale116.314,787556,77644,412Feb 08 07:16 PM
Franchini Indrani LallEVP, Chief Compliance OfficerFeb 08Sale116.311,459169,69625,031Feb 08 07:16 PM
Clancy Paul JEVP, Chief Financial OfficerFeb 08Sale116.316,079707,04889,014Feb 08 07:17 PM
Wagner Heidi LSVP, Global Government AffairsFeb 08Sale116.311,774206,33449,838Feb 08 07:17 PM
HANTSON LUDWIGCEOFeb 08Sale116.3113,2451,540,526118,180Feb 08 07:16 PM
Wagner Heidi LSVP, Global Government AffairsFeb 05Sale117.2665576,80532,635Feb 07 06:36 PM
O'Neill JulieEVP. Global OperationsFeb 05Sale117.262,119248,47420,210Feb 07 06:35 PM
Moriarty John BEVP & General CounselFeb 05Sale117.261,261147,86549,911Feb 07 06:35 PM
HANTSON LUDWIGCEOJan 02Sale121.632,553310,52136,172Jan 04 06:33 PM